LegoChem Biosciences Inc (141080) - Total Assets
Based on the latest financial reports, LegoChem Biosciences Inc (141080) holds total assets worth ₩699.43 Billion KRW (≈ $473.99 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is LegoChem Biosciences Inc's book value for net asset value and shareholders' equity analysis.
LegoChem Biosciences Inc - Total Assets Trend (2014–2024)
This chart illustrates how LegoChem Biosciences Inc's total assets have evolved over time, based on quarterly financial data.
LegoChem Biosciences Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
LegoChem Biosciences Inc's total assets of ₩699.43 Billion consist of 74.5% current assets and 25.5% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 17.5% |
| Accounts Receivable | ₩13.72 Billion | 1.9% |
| Inventory | ₩212.47 Million | 0.0% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩8.44 Billion | 1.1% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how LegoChem Biosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 141080 market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: LegoChem Biosciences Inc's current assets represent 74.5% of total assets in 2024, a decrease from 90.7% in 2014.
- Cash Position: Cash and equivalents constituted 17.5% of total assets in 2024, up from 4.8% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 1.9% of total assets.
LegoChem Biosciences Inc Competitors by Total Assets
Key competitors of LegoChem Biosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.06 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥819.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.16 Billion |
LegoChem Biosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.97 | 6.81 | 7.14 |
| Quick Ratio | 8.96 | 6.81 | 7.12 |
| Cash Ratio | 0.00 | 0.47 | 0.00 |
| Working Capital | ₩529.18 Billion | ₩479.78 Billion | ₩86.00 Billion |
LegoChem Biosciences Inc - Advanced Valuation Insights
This section examines the relationship between LegoChem Biosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 11.61 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 289.6% |
| Total Assets | ₩738.38 Billion |
| Market Capitalization | $4.52 Billion USD |
Valuation Analysis
Below Book Valuation: The market values LegoChem Biosciences Inc's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: LegoChem Biosciences Inc's assets grew by 289.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for LegoChem Biosciences Inc (2014–2024)
The table below shows the annual total assets of LegoChem Biosciences Inc from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩738.38 Billion ≈ $500.39 Million |
+289.64% |
| 2023-12-31 | ₩189.50 Billion ≈ $128.42 Million |
-24.96% |
| 2022-12-31 | ₩252.53 Billion ≈ $171.14 Million |
-13.88% |
| 2021-12-31 | ₩293.23 Billion ≈ $198.72 Million |
+115.75% |
| 2020-12-31 | ₩135.91 Billion ≈ $92.11 Million |
-3.93% |
| 2019-12-31 | ₩141.48 Billion ≈ $95.88 Million |
+16.26% |
| 2018-12-31 | ₩121.69 Billion ≈ $82.47 Million |
+47.97% |
| 2017-12-31 | ₩82.24 Billion ≈ $55.73 Million |
-8.17% |
| 2016-12-31 | ₩89.55 Billion ≈ $60.69 Million |
+30.84% |
| 2015-12-31 | ₩68.44 Billion ≈ $46.38 Million |
+102.75% |
| 2014-12-31 | ₩33.76 Billion ≈ $22.88 Million |
-- |
About LegoChem Biosciences Inc
LigaChem Biosciences Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of medicines for unmet medical needs. The company researches and develops products for various therapeutic areas, including antibiotics, anti-fibrotics, immuno-oncology, oncology; and antibody-drug conjugate (ADC) platform technology and small molecule drugs. It also sells medical devic… Read more